GAO: Oversight of imported radiological material needs to be improved

On Jan. 12, the U.S. Government Accounting Office (GAO) published a 28-page report on its website that called for U.S. Customs and Border Protection (CBP) to improve its ability to verify the licenses of imported radiological material.

“GAO recommends that CBP develop a monitoring system to help ensure that CBP officials comply with the agency’s license verification policy, conduct an assessment to determine relevant information that is not included in the automated alerts, and develop a system that allows it to identify shipments of greatest risk,” according to the GAO report.

The U.S. Nuclear Regulatory Commission regulates the possession and import of such materials, though the CPB is required to verify shipments entering the U.S. The newly released report examined the CPB’s policies and the effectiveness of these policies.

The GAO had three recommendations:

  1. CBP should develop a monitoring system to help ensure that CBP officials comply with license verification policies and procedures.
  2. CBP should conduct a comprehensive assessment of information not included in the automated alert to determine what information is needed to identify licensable radiological material.
  3. CBP should develop a system that better identifies shipments of radiological material that pose the greatest risk and revise CBP’s policies and procedures as necessary to verify licenses for these shipments.
""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.